SecurityLJPC / La Jolla Pharmaceutical Co. (503459604)
President, CEO & SecretaryTIDMARSH GEORGE F
Form 4 Count97
Form 8-K Count83
Form SC 13G/A Count35
Form 10-Q Count20

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to La Jolla Pharmaceutical Co.


DateFormTitle
2018-09-18 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-08-22 DEF 14A LJPC / La Jolla Pharmaceutical Co. DEF 14A
2018-08-08 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-08-08 10-Q LJPC / La Jolla Pharmaceutical Co. 10-Q (Quarterly Report)
2018-05-14 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-05-10 10-Q LJPC / La Jolla Pharmaceutical Co. 10-Q (Quarterly Report)
2018-04-30 10-K/A LJPC / La Jolla Pharmaceutical Co. 10-K/A (Annual Report)
2018-04-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)
2018-04-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - null (Passive Investment)
2018-03-27 CT ORDER LJPC / La Jolla Pharmaceutical Co. null
2018-03-20 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 10 (Activist Investment)
2018-03-20 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 10 (Activist Investment)
2018-03-19 8-K LJPC / La Jolla Pharmaceutical Co. FORM 8-K (Current Report)
2018-03-16 424B5 LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)
2018-03-14 424B5 LJPC / La Jolla Pharmaceutical Co. 424B5 (Prospectus)
2018-03-01 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 9 (Activist Investment)
2018-03-01 SC 13D/A LJPC / La Jolla Pharmaceutical Co. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 9 (Activist Investment)
2018-02-22 10-K LJPC / La Jolla Pharmaceutical Co. 10-K (Annual Report)
2018-02-14 SC 13G LJPC / La Jolla Pharmaceutical Co. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)
2018-02-14 SC 13G LJPC / La Jolla Pharmaceutical Co. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP (Passive Investment)
2018-02-14 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / RTW INVESTMENTS, LLC - 3G/A (Passive Investment)
2018-02-14 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / RTW INVESTMENTS, LLC - 3G/A (Passive Investment)
2018-02-13 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-13 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FMR LLC / Fidelity - 3G/A (Passive Investment)
2018-02-07 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)
2018-02-07 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / FRANKLIN RESOURCES INC - 3G/A (Passive Investment)
2018-02-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)
2018-02-06 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / JANUS CAPITAL MANAGEMENT LLC - JANUS CAPITAL MANAGEMENT 12/31/17 <5% ANNUAL CLOSEOUT (Passive Investment)
2018-02-05 SC 13G LJPC / La Jolla Pharmaceutical Co. / JENNISON ASSOCIATES LLC - 13G INITIAL ANNUAL FILING - IJPC (Passive Investment)
2018-02-05 SC 13G LJPC / La Jolla Pharmaceutical Co. / JENNISON ASSOCIATES LLC - 13G INITIAL ANNUAL FILING - IJPC (Passive Investment)
2018-02-01 SC 13G LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - 3G (Passive Investment)
2018-02-01 SC 13G LJPC / La Jolla Pharmaceutical Co. / BlackRock Inc. - 3G (Passive Investment)
2018-01-30 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2018-01-26 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PRUDENTIAL FINANCIAL INC - 3G/A (Passive Investment)
2018-01-26 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PRUDENTIAL FINANCIAL INC - 3G/A (Passive Investment)
2018-01-11 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G/A (Passive Investment)
2018-01-11 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G/A (Passive Investment)
2018-01-11 SC 13G LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G (Passive Investment)
2018-01-11 SC 13G LJPC / La Jolla Pharmaceutical Co. / Broadfin Capital, LLC - 3G (Passive Investment)
2017-12-31 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2017-12-28 8-K LJPC / La Jolla Pharmaceutical Co. 8-K (Current Report)
2017-12-18 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)
2017-12-18 SC 13G/A LJPC / La Jolla Pharmaceutical Co. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G (Passive Investment)
2017-12-31 CORRESP LJPC / La Jolla Pharmaceutical Co. ESP
2018-01-01 LETTER LJPC / La Jolla Pharmaceutical Co. ER
2017-10-30 8-K La Jolla Pharmaceutical 8-K (Current Report/Significant Event)
2017-10-28 S-3 La Jolla Pharmaceutical FORM S-3
2017-10-28 S-8 La Jolla Pharmaceutical S-8
2017-10-27 10-Q La Jolla Pharmaceutical 10-Q (Quarterly Report)
2017-10-10 SC 13G La Jolla Pharmaceutical 3G (Passive Acquisition of More Than 5% of Shares)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 503459604